Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Consensus Rating of “Reduce” from Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received a consensus recommendation of “Reduce” from the nine analysts that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $28.00.

Several research analysts have recently commented on the company. Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, January 27th. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a report on Tuesday, February 24th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Erste Group Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 14.2% during the first quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock worth $356,000 after purchasing an additional 1,777 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 160.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 37,610 shares of the company’s stock worth $1,075,000 after purchasing an additional 23,163 shares in the last quarter. Franklin Resources Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 3.8% during the 2nd quarter. Franklin Resources Inc. now owns 75,034 shares of the company’s stock worth $2,144,000 after buying an additional 2,760 shares during the last quarter. American Century Companies Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 21.3% during the 2nd quarter. American Century Companies Inc. now owns 29,173 shares of the company’s stock worth $833,000 after buying an additional 5,127 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at about $587,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock opened at $22.36 on Thursday. The firm has a market cap of $12.49 billion, a price-to-earnings ratio of 11.71, a PEG ratio of 2.14 and a beta of 0.89. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $20.94 and a 52-week high of $30.46. The company has a quick ratio of 0.92, a current ratio of 1.26 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $23.08 and its 200 day moving average is $24.06.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Saturday, February 14th. The company reported $1.69 earnings per share for the quarter. The company had revenue of $5.95 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%. On average, sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.